Lader M, Olajide D
J Clin Psychopharmacol. 1987 Feb;7(1):11-5.
Buspirone is a new antianxiety compound of a totally new type which may avoid the dependence problems of its predecessors. This study was designed to evaluate any possible cross-tolerance to the benzodiazepines. Twenty-four outpatients on long-term therapeutic dose benzodiazepine treatment, who wished to discontinue treatment, were allocated randomly to placebo substitution or buspirone substitution and then withdrawal over a total of 10 weeks. Assessments were made at weekly intervals. Of the 24 patients entered into the trial, 13 received buspirone and 11 placebo. Only five of the buspirone and six of the placebo patients successfully completed withdrawal. Some anxiolytic action of buspirone was detected, but it was insufficient to materially assist the withdrawal. No evidence was found that buspirone was cross-tolerant to the benzodiazepines. It was concluded that buspirone does not help benzodiazepine withdrawal and does not suppress benzodiazepine withdrawal symptoms.
丁螺环酮是一种全新类型的新型抗焦虑化合物，可能避免了其前代药物的依赖性问题。本研究旨在评估对苯二氮䓬类药物是否存在任何可能的交叉耐受性。24名长期接受苯二氮䓬类药物治疗且希望停药的门诊患者被随机分配至安慰剂替代组或丁螺环酮替代组，然后在总共10周的时间内逐渐停药。每周进行评估。进入试验的24名患者中，13名接受丁螺环酮治疗，11名接受安慰剂治疗。丁螺环酮组仅有5名患者和安慰剂组6名患者成功完成停药。检测到丁螺环酮有一定抗焦虑作用，但不足以实质性地帮助停药。未发现丁螺环酮对苯二氮䓬类药物有交叉耐受性的证据。得出的结论是，丁螺环酮无助于苯二氮䓬类药物的停药，也不能抑制苯二氮䓬类药物的戒断症状。
